AP
AEGR

Alydar Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

Alydar Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-125,000
Closed -$8.87M – 138
2013
Q4 		$8.87M Buy
+125,000
New +$9.56M 0.9% 35

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Alydar Partners's AEGR Position: Q1 2014 in Review

Alydar Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2014, closing a stake of 125,000 shares — an estimated $8.87M sold.

Alydar Partners first reported a position in AEGR in Q4 2013 and held it in 1 quarter. The position peaked at $8.87M in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q1 2014.

  • Alydar Partners reported no remaining Aegerion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Alydar Partners sold 125,000 Aegerion Pharmaceuticals shares in Q1 2014, an estimated $8.87M.
  • Alydar Partners first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Alydar Partners's Aegerion Pharmaceuticals position peaked at $8.87M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2014.

Based on Alydar Partners's 13F filing for Q1 2014, filed 15 May 2014.